+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Transgenic expression of kallikrein prevents left ventricular dysfunction and inhibits endothelial induction of ICAM-1 and intramyocardial LFA-1/Mac-1+ infiltration in streptozotocin-induced diabetic cardiopathy in rats



Transgenic expression of kallikrein prevents left ventricular dysfunction and inhibits endothelial induction of ICAM-1 and intramyocardial LFA-1/Mac-1+ infiltration in streptozotocin-induced diabetic cardiopathy in rats



Circulation 104(17 Suppl.): II 198




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035974130

Download citation: RISBibTeXText


Related references

Transgenic expression of kallikrein prevents from diabetic cardiomyopathy by inhibition of ICAM-1 induction and infiltration. European Heart Journal 23(Abstract Suppl.): 205, August-September, 2002

Transgenic activation of the kallikrein-kinin system reduces intramyocardial expression of TNFa and II-1b and improves left ventricular function in experimental diabetic cardiopathy. European Heart Journal 22(Abstract Suppl.): 680, 2001

Transgenic activation of the kallikrein-kinin system prevents streptozotocin-diabetic hearts from cardiac fibrosis and left ventricular dysfunction. European Heart Journal 22(Abstract Suppl.): 54, 2001

Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. Faseb Journal 19(14): 2057-2059, 2005

Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. Faseb Journal 18(7): 828-835, 2004

Transgenic expression of human kallikrein prevents altered left ventricular function, the decline in sarcoplasmic reticulum calcium pump activity and the rise in cardiac collagen content in diabetic rats. Circulation 102(18 Suppl.): II 267, 2000

Left ventricular dysfunction and remodeling in streptozotocin-induced diabetic rats. Circulation Journal 70(3): 327-334, 2006

Transgenic expression of human kallikrein prevents sarcoplasmic reticular calcium ion transport dysfunction in diabetic rat heart. Hypertension 36(4): 655, 2000

Taurine rescues vascular endothelial dysfunction in streptozocin-induced diabetic rats: correlated with downregulation of LOX-1 and ICAM-1 expression on aortas. European Journal of Pharmacology 597(1-3): 75-80, 2008

Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats. Cardiovascular Diabetology 10: 105, 2012

Endothelial dysfunction, macrophage infiltration and NADPH oxidase-dependent superoxide production were attenuated by erythropoietin in streptozotocin-induced diabetic rat aorta. Pharmacology 91(1-2): 48-58, 2013

Transgenic overexpression of insulin-like growth factor I prevents streptozotocin-induced cardiac contractile dysfunction and beta-adrenergic response in ventricular myocytes. Journal of Endocrinology 180(1): 175-182, 2004

Transgenic expression of human kallikrein prevents haemodynamic alterations and decline in sarcoplasmic reticulum calcium pump activity in diabetic rats. European Heart Journal 21(Abstract Suppl.): 3, August-September, 2000

Spironolactone improves endothelial dysfunction in streptozotocin-induced diabetic rats. Naunyn-Schmiedeberg's Archives of Pharmacology 387(12): 1187-1197, 2015

Carvedilol ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats. European Journal of Pharmacology 567(3): 223-230, 2007